12 research outputs found
Meningococcal infections in hospitalised patients in Pretoria
We report on 13 patients diagnosed with meningococcal infections
in patients attending state-owned hospitals serving an indigent
population in Pretoria in 2009. The case fatality rate was 27%.
Ceftriaxone was the main antibiotic (9 out of 13 patients) for therapy.
Five isolates (39%) were serogroup B and 4 (31%) serogroup W135.
Most isolates (12/13) were fully susceptible to penicillin (MIC range
0.016 - 0.047 μg/ml). A single isolate was intermediately resistant
to penicillin (MIC, 0.125 μg/ml) while all isolates were uniformly
susceptible to ceftriaxone, ciprofloxacin and rifampicin. This
pattern reveals a shift in serogroups with an increase of serogroup B
disease in the Pretoria region, and the need for ongoing monitoring
of antimicrobial susceptibility profiles and the value of ceftriaxone
for favourable therapeutic outcome.http://www.samj.org.z
Recommendations for the medical evaluation of children prior to adoption in South Africa
The current legislative framework in South Africa (SA) supports adoption as the preferred form of care for children with inadequate or
no parental or family support. There are an estimated 3.8 million orphans in SA, with approximately 1.5 - 2 million children considered
adoptable. As a means of improving services, newly drafted adoption guidelines from the National Department of Social Development will
in future require both non-profit and private sector adoption agencies to obtain a medical report on a child prior to placement. However,
no local guidelines specify what an appropriate medical examination entails or how it should be reported. For the purposes of proposing
and developing such guidelines, an open forum was convened at the Institute of Pathology, University of Pretoria, in March 2013. These
‘Recommendations for the medical evaluation of children prior to adoption in South Africa’ emanate from this meeting.http://www.samj.org.zaam201
Recommendations for the medical evaluation of children prior to adoption in South Africa
The current legislative framework in South Africa (SA) supports adoption as the preferred form of care for children with inadequate or
no parental or family support. There are an estimated 3.8 million orphans in SA, with approximately 1.5 - 2 million children considered
adoptable. As a means of improving services, newly drafted adoption guidelines from the National Department of Social Development will
in future require both non-profit and private sector adoption agencies to obtain a medical report on a child prior to placement. However,
no local guidelines specify what an appropriate medical examination entails or how it should be reported. For the purposes of proposing
and developing such guidelines, an open forum was convened at the Institute of Pathology, University of Pretoria, in March 2013. These
‘Recommendations for the medical evaluation of children prior to adoption in South Africa’ emanate from this meeting.http://www.samj.org.zaam201
National sentinel site surveillance for antimicrobial resistance in Klebsiella pneumoniae isolates in South Africa, 2010 - 2012
BACKGROUND. The increasing rates of antimicrobial resistance observed in the nosocomial pathogen Klebsiella pneumoniae are of major
public health concern worldwide.
Objectives. To describe the antibiotic susceptibility profiles of K. pneumoniae isolates from bacteraemic patients submitted by sentinel
laboratories in five regions of South Africa from mid-2010 to mid-2012. Molecular methods were used to detect the most commonly found
extended-spectrum beta-lactamase (ESBL) and carbapenemase resistance genes.
METHODS. Thirteen academic centres serving the public healthcare sector in Gauteng, KwaZulu-Natal, Free State, Limpopo and Western
Cape provinces submitted K. pneumoniae isolates from patients with bloodstream infections. Vitek 2 and MicroScan instruments were used
for organism identification and susceptibility testing. Multiplex polymerase chain reactions (PCRs) were used to detect blaCTX-M, blaSHV and
blaTEM genes in a proportion of the ESBL isolates. All isolates exhibiting reduced susceptibility to carbapenems were PCR tested for blaKPC
and blaNDM-1 resistance genes.
RESULTS. Overall, 68.3% of the 2 774 isolates were ESBL-positive, showing resistance to cefotaxime, ceftazidime and cefepime. Furthermore,
46.5% of all isolates were resistant to ciprofloxacin and 33.1% to piperacillin-tazobactam. The major ESBL genes were abundantly present
in the sample analysed. Most isolates (95.5%) were susceptible to the carbapenems tested, and no isolates were positive for blaKPC or blaNDM-1.
There was a trend towards a decrease in susceptibility to most antibiotics.
CONCLUSION. The high proportion of ESBL-producing K. pneumoniae isolates observed, and the prevalence of ESBL genes, are of great
concern. Our findings represent a baseline for further surveillance in SA, and can be used for policy and treatment decisions.http://www.samj.org.zaam201
Infection prevention and control for viral infections
Infection prevention and control (IPC) is the new terminology used for what was previously referred to as simply 'infection control'. It is an important component of health care and all health care workers (doctors, nurses, allied health workers, etc.) need to know at least the essential principles of infection prevention and control, as this will equip them with the knowledge and skills needed to provide safe and effective health care.http://www.cmej.org.za/index.php/cme
Clostridium difficile infections in a tertiary hospital : value of surveillance
No abstract available
Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa
Abstract Background The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing and the emergence of extensively drug-resistant tuberculosis (XDR-TB) is a major challenge. Controlling resistance, reducing transmission and improving treatment outcomes in MDR/XDR-TB patients is reliant on susceptibility testing. Susceptibility testing using phenotypic methods is labour intensive and time-consuming. Alternative methods, such as molecular assays are easier to perform and have a rapid turn-around time. The World Health Organization (WHO) has endorsed the use of line probe assays (LPAs) for first and second line diagnostic screening of MDR/XDR-TB. Methods We compared the performance of LPAs to BACTEC MGIT 960 system for susceptibility testing of bacterial resistance to first-line drugs: rifampicin (RIF), isoniazid (INH), ethambutol (EMB), and second-line drugs ofloxacin (OFL) and kanamycin (KAN). One hundred (100) consecutive non-repeat Mycobacterium tuberculosis cultures, resistant to either INH or RIF or both, as identified by BACTEC MGIT 960 were tested. All isoniazid resistant cultures (n = 97) and RIF resistant cultures (n = 90) were processed with Genotype®MTBDRplus and Genotype®MTBDRsl line probe assays (LPAs). The agar proportion method was employed to further analyze discordant LPAs and the MGIT 960 isolates. Results The Genotype ®MTBDRplus (version 2) sensitivity, specificity, PPV and NPV from culture isolates were as follows: RIF, 100%, 87.9, 58.3% and 100%; INH, 100%, 94.4%, 93.5% and 100%. The sensitivity, specificity PPV and NPV for Genotype ® MTBDRsl (version 1 and 2) from culture isolates were as follows: EMB, 60.0%, 89.2%, 68.2% and 85.3%; OFL, 100%, 91.4%, 56.2% and 100%; KAN, 100%, 97.7%, 60.0% and 100%. Line probe assay showed an excellent agreement (k = 0.93) for INH susceptibility testing when compared to MGIT 960 system while there was good agreement (k = 0.6–0.7) between both methods for RIF, OFL, KAN testing and moderate agreement for EMB (k = 0.5). A high RIF mono-resistance (MGIT 960 33/97 and LPA 43/97) was observed. Conclusion LPAs are an efficient and reliable rapid molecular DST assay for rapid susceptibility screening of MDR and XDR-TB. Using LPAs in high MDR/XDR burden countries allows for appropriate and timely treatment, which will reduce transmission rates, morbidity and improve treatment outcomes in patients
In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
BACKGROUND: The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa.
AIM: The aim of this study was to evaluate the in vitro activity of tigecycline against carbapenem resistant A. baumannii complex.
METHODS: Consecutive clinical isolates of carbapenem resistant A. baumannii complex were collected between February and July 2010. Species identification and susceptibility testing was performed by Vitek-2 colorimetric compact system with Advanced Expert System (AES). Strains were tested for carbapenemase production by the
modified Hodge test, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.
RESULTS: A total of 232 carbapenem resistant clinical isolates of A. baumannii complex were collected over the six months study period; 217 (93.5%) of these were modified Hodge test positive. All isolates were susceptible to colistin and 174 (78%) susceptible to amikacin whilst 20 (9%) were susceptible to ciprofloxacin. For tigecycline 169
(75.8%) were fully susceptible, 37 (16.6%) intermediately resistant and only 17 (7.6%) were fully resistant. None of the carbapenem resistant isolates were susceptible to ampicillin, amoxicillin/clavullanic acid, piperacillin/tazobactam, cefuroxime, cefuroxime axetil, cefoxitin, cefepime or nitrofurantoin.
CONCLUSION: All carbapenem resistant isolates were found to be fully susceptible to colistin; amikacin and tigecycline susceptibility was 78% and 76% respectively. Treatment options for infections due to carbapenem and multi-drug resistant A. baumannii organisms are limited and hence tigecycline and amikacin may be considered.
The properties of tigecycline i.e. stability, safety, low toxicity, non cross-resistance with other antibiotics and its efficacy against multi-drug resistant A. baumannii isolates make it a good choice. However, ongoing monitoring of A. baumannii susceptibility to tigecycline is needed.http://www.biomedcentral.com/1756-0500/5/21
A forgotten nosocomial bacterium (Chryseobacterium meningosepticum)
No abstract available
A forgotten nosocomial bacterium (Chryseobacterium meningosepticum)
No abstract available